Previous 10 | Next 10 |
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on November 3, 2022 – NEW YORK , Oct. 27, 2022 /PRNewswir...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Rokas Tenys / Shutterstock.com Twitter (NYSE: TWTR ) stock is a hot topic among traders today as they react to reports of new backing for Elon Musk’s acquisition of the social media company. Acc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: NicoElNino / Shutterstock.com Veris Residential (NYSE: VRE ) stock is rising higher on Friday after the company received a buyout offer from Kushner Companies . That offer, which is unsolicited, has...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Immunic (NASDAQ: IMUX ) stock is plummeting on Friday after the company reported a high placebo rate in a Phase 1b clinical trial. This trial is currently ongoing and is testing the effe...
Immunic ( NASDAQ: IMUX ) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plung...
Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate PR Newswire – Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo – – N...
Summary The MS market is highly saturated. Although there's a lot of lacunae, new MS drugs need to show exactly why they should exist. Immunic's MS drug is yet to convincingly show this. Immunic ( IMUX ) shares more than doubled recently after a successful, ove...
Immunic ( NASDAQ: IMUX ) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredi...
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing PR Newswire NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a clinical-stage biopharmaceutical company developi...
Immunic to Participate in Scientific and Industry Conferences in October PR Newswire NEW YORK , Oct. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology th...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...